Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin-conjugated Fibrin Matrix with Autologous MSCs + TGF-β1 + BMP-4
- Development stage
- Unknown
- Lead developer
- National Scientific Center of Traumatology and Orthopedics Named after Academician N.D. Batpenov
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
This experimental regenerative therapy is an injectable biocomposite hydrogel developed by the National Scientific Center of Traumatology and Orthopedics Named after Academician N.D. Batpenov. It consists of a heparin-conjugated fibrin matrix (HCFM) that serves as a delivery vehicle and scaffold for autologous mesenchymal stem cells (MSCs) and two potent chondroinductive growth factors: Transforming Growth Factor-beta 1 (TGF-β1) and Bone Morphogenetic Protein 4 (BMP-4). The heparin conjugation within the fibrin matrix allows for the sustained and controlled release of these growth factors, which work synergistically to promote the differentiation of MSCs into chondrocytes and facilitate the repair of cartilage and osteochondral tissues. The therapy is primarily targeted at treating degenerative and traumatic joint conditions, specifically ankle osteoarthritis and osteochondral defects of the talus.
- Other names
- Heparin-conjugated Fibrin Matrix with Autologous MSCs + TGF-β1 + BMP-4NSCTO biocomposite hydrogelInjectable regenerative scaffold with MSCs, TGF-β1, and BMP-4
Beyond the preview
Go deeper on Heparin-conjugated Fibrin Matrix with Autologous MSCs + TGF-β1 + BMP-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heparin-conjugated Fibrin Matrix with Autologous MSCs + TGF-β1 + BMP-4.